The PEARL-III study included a total of 419 GT1b treatment-naïve patients with no evidence of liver cirrhosis, out of which 209 were randomised to the
regimen without ribavirin for 12 weeks, and 210 were randomised to the
regimen plus ribavirin for 12 weeks.
After 12 weeks of treatment, 99% of patients receiving the regimen without ribavirin (n=207/209) and 99% of them receiving the regimen plus ribavirin (n=209/210) achieved SVR12.